       Document 0642
 DOCN  M95A0642
 TI    Evolution of natural killer (NK) function in HIV+ children. American
       Pediatric Society 104th annual meeting and Society for Pediatric
       Research 63rd annual meeting; 1994 May 2-5; Seattle.
 DT    9510
 AU    Schuval SJ; Hatam L; Bonagura VR; Dept. Peds. Schneider Children's
       Hospital, Long Island Jewish; Medical Center, New Hyde Park, NY 10042,
       USA.
 SO    Pediatr AIDS HIV Infect. 1994 Oct;5(5):315 (unnumbered abstract). Unique
       Identifier : AIDSLINE AIDS/95330402
 AB    We previously identified NK deficiency in HIV+ infants (mean < or = 28.3
       +/- 15.1 mos.). Some of these children had Pneumocystis carinii
       pneumonia (PCP) despite normal CD4+ T-cell numbers. To determine if this
       NK deficiency persists during childhood, we restudied 5 of these
       children and 5 others. 8/10 were on anti-retroviral therapy (AZT, ddI,
       or ddC). We developed an NK cytolytic assay using flow cytometry to
       study these 10 older HIV+ children (mean 7.54 +/- 4.7 yrs). This flow
       cytometric method is comparable to the 51Cr release assay. TABULAR DATA,
       SEE PUBLISHED ABSTRACT. (*one-tailed Mann Whitney U test) 5/10 showed
       normal NK cytolysis independent of CD4+ T-cell number. 3/5 of the
       original NK deficient infants (2 on anti-retroviral therapy) showed
       normal NK function. 2 new children, 1 treated, also had normal NK
       function. However, IFN-a did not boost NK function to control levels in
       any HIV+ child, whereas r-IL2 did. Therefore, some older HIV+ children
       can show normal NK function. However, the expected boost in NK cytolysis
       from IFN-a is absent and may serve as a disease marker. NK cytolysis
       restoration in HIV+ children may be age and/or treatment related.
 DE    Antigens, CD/ANALYSIS  Antigens, Differentiation, T-Lymphocyte/ANALYSIS
       Antiviral Agents/THERAPEUTIC USE  Child, Preschool  Cytotoxicity,
       Immunologic  Flow Cytometry  Human  HIV Seropositivity/DRUG
       THERAPY/*IMMUNOLOGY  Infant  Interferon-alpha/PHARMACOLOGY
       Interleukin-2/PHARMACOLOGY  Killer Cells, Natural/*IMMUNOLOGY  MEETING
       ABSTRACT  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

